Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2115 July 2024

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Erlotinib		
Initial application Applications only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.  Prerequisites(tick boxes where appropriate)  Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)  There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase  Patient is treatment naive  or  The patient has discontinued gefitinib due to intolerance and The cancer did not progress while on gefitinib  Erlotinib is to be given for a maximum of 3 months		
Renewal  Current approval Number (if known):		
and Erlotinib to be discontinued at prog	als valid for 6 months.  rom treatment and continued treatment remains appr	

I confirm the above details are correct and that in signing this form I understand I may be audited.